Current management of stage IV nasopharyngeal carcinoma without distant metastasis.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biopsy, Needle
Cause of Death
Chemoradiotherapy
/ methods
Combined Modality Therapy
Disease-Free Survival
Female
Humans
Immunohistochemistry
Induction Chemotherapy
/ methods
Male
Nasopharyngeal Carcinoma
/ diagnostic imaging
Nasopharyngeal Neoplasms
/ diagnostic imaging
Neoplasm Invasiveness
/ pathology
Neoplasm Metastasis
Neoplasm Staging
Positron-Emission Tomography
/ methods
Prognosis
Risk Assessment
Survival Analysis
Treatment Outcome
Chemotherapy
Immunotherapy
Nasopharyngeal carcinoma
Prognosis
Radiotherapy
Targeted therapy
Journal
Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
17
01
2020
revised:
17
02
2020
accepted:
19
02
2020
pubmed:
1
3
2020
medline:
25
3
2020
entrez:
1
3
2020
Statut:
ppublish
Résumé
Up to one in four patients with nasopharyngeal carcinoma present with non-metastatic stage IV disease (i.e. T4 or N3). Distinct failure patterns exist, despite the routine adoption of contemporary treatment modalities such as intensity modulated radiotherapy and systemic chemotherapy. Concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy or induction chemotherapy followed by CCRT are commonly employed in this setting, with the latter emerging as the preferred option. Additionally, emerging radiation technologies like proton therapy has become available offering new opportunities for prevention of radiation-induced side effects. This article reviews not only the current treatment strategies, but also discusses novel ways to tackle this challenging disease with respect to the patterns of failure.
Identifiants
pubmed: 32113080
pii: S0305-7372(20)30033-5
doi: 10.1016/j.ctrv.2020.101995
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101995Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JA Langendijk: Departmental research collaboration with RaySearch, IBA, Siemens, Mirada and Elekta. Member of the International Advisory Board of IBA, honorarium paid to UMCG Research BV. Nabil F. Saba: Consulting for Merck, Aduro, Rakuten, Pfizer, CUE, Blupoint